Financial Contrast: Synlogic (NASDAQ:SYBX) versus Kyntra Bio (NASDAQ:KYNB)

Kyntra Bio (NASDAQ:KYNB) and Synlogic (NASDAQ:SYBX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Kyntra Bio and Synlogic, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1	1	4	0	2.50
Synlogic	1	0	0	0	1.00

Kyntra Bio presently has a consensus price target of $37.25, suggesting a potential upside of 436.74%. Given Kyntra Bio’s stronger consensus rating and higher probable upside, equities analysts clearly believe Kyntra Bio is more favorable than Synlogic.

Risk & Volatility

Kyntra Bio has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, Synlogic has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500.

Institutional and Insider Ownership

72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 63.4% of Synlogic shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by insiders. Comparatively, 2.6% of Synlogic shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Kyntra Bio and Synlogic’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-47.27%
Synlogic	N/A	-26.47%	-18.00%

Valuation and Earnings

This table compares Kyntra Bio and Synlogic”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$4.62 million	6.09	$183.45 million	$45.30	0.15
Synlogic	$8,000.00	1,714.86	-$23.36 million	($0.06)	-18.67

Kyntra Bio has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Summary

Kyntra Bio beats Synlogic on 12 of the 14 factors compared between the two stocks.

About Kyntra Bio

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

About Synlogic

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.